Paragonix Technologies

Executive Summary

Paragonix Technologies, headquartered in Cambridge, MA, is a pioneering medical device company dedicated to advancing organ transplantation through innovative preservation technology. Founded in 2010, the company has developed a suite of products and services designed to optimize the donor organ procurement journey, from recovery to transplantation. Their flagship SherpaPak system provides precise temperature control and standardized transport, addressing critical challenges in organ preservation such as ischemic injury and timing constraints. By combining proprietary hardware with data-driven monitoring and logistics support, Paragonix aims to improve transplant outcomes and expand the viable donor organ pool. With a focus on clinical evidence and regulatory excellence, the company has established itself as a key player in the organ preservation market, which is projected to grow significantly due to rising demand for transplants and advancements in transplantation medicine.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation SherpaPak system75% success
• Q4 2026Positive results from clinical trial of paragonix liver preservation system60% success
• Q2 2026Strategic partnership with major transplant center network for expanded deployment70% success